(New Delhi, February 3, 2025)
Poly Medicure Limited (NSE: POLYMED, BSE: 531768) has announced its
unaudited standalone and consolidated financial results for the third quarter and nine months ended
December 31, 2024, following the approval by the Board of Directors.
Key Financial Highlights (₹ in lakh)
| Particulars | Q3 FY25 (Standalone) | Q3 FY25 (Consolidated) | Q3 FY24 (Standalone) | Q3 FY24 (Consolidated) |
|---|
| Revenue from Operations | 41,093.71 | 42,421.19 | 32,086.35 | 33,959.82 |
| Total Income | 43,268.49 | 44,601.28 | 33,742.84 | 35,616.58 |
| EBITDA | 11,338.99 | 11,322.63 | 8,208.97 | 8,782.46 |
| Profit Before Tax (PBT) | 11,338.99 | 11,798.21 | 8,208.97 | 8,782.46 |
| Profit After Tax (PAT) | 8,515.16 | 8,172.02 | 6,146.08 | 6,501.59 |
| Earnings Per Share (EPS) – Basic (₹) | 8.48 | 8.48 | 6.41 | 6.78 |
- Consolidated Revenue grew 24.9% YoY to ₹44,601.28 lakh.
- Standalone PAT surged 38.5% YoY to ₹8,515.16 lakh.
- EBITDA Margin remains strong at approximately 25.4%.
Nine-Month Performance FY25 (April-December 2024)
| Particulars | Standalone (₹ in lakh) | Consolidated (₹ in lakh) |
|---|
| Revenue from Operations | 1,18,083.64 | 1,22,900.38 |
| Total Income | 1,24,665.42 | 1,29,387.15 |
| Profit Before Tax (PBT) | 32,639.47 | 34,966.58 |
| Profit After Tax (PAT) | 24,318.70 | 24,672.29 |
Poly Medicure maintained a strong revenue trajectory with
25.1% YoY growth in revenue and
32.9% YoY growth in consolidated PAT.
Strategic Announcements & Developments
- Equity Share Issuance:
- The company allotted 35,150 equity shares under the Employee Stock Option Scheme (ESOS) 2020 at ₹100 per share.
- Raised ₹99,999.98 lakh via Qualified Institutional Placement (QIP) at an issue price of ₹1,880 per share.
- QIP proceeds were utilized for:
- ₹1,460.50 lakh towards share issue expenses.
- ₹8,499.98 lakh for working capital repayment.
- ₹90,039.50 lakh temporarily invested in liquid mutual funds.
- Subsidiary & Associate Performance:
- Poly Medicure (Laiyang) Co. Ltd. (China)
- Poly Medicure B.V. (Netherlands)
- Plan 1 Health India Pvt Ltd.
- Ultra for Medical Products Co. (Egypt, Associate)
- Dividend & Shareholder Value Enhancement:
- The company continues to focus on shareholder value through strong earnings growth and strategic reinvestments.
Management Commentary
Himanshu Baid,
Managing Director, stated:
"We continue to witness strong growth momentum driven by increased demand in medical devices. Our QIP funding further strengthens our financial position and enables us to pursue strategic expansions and R&D investments."
Outlook
- Expansion in International Markets
- Strong R&D Pipeline
- Focus on Margin Expansion & Operational Efficiency
Poly Medicure remains
optimistic about its growth trajectory, backed by strong fundamentals, robust financial health, and a
strategic vision for global expansion.
Stock Market Response
With solid earnings performance and continued growth prospects,
Poly Medicure's stock is expected to remain attractive for investors seeking
long-term value creation.